Simvastatin Inhibits Glucose Metabolism and Legumain Activity in Human Myotubes
Simvastatin, a HMG-CoA reductase inhibitor, is prescribed worldwide to patients with hypercholesterolemia. Although simvastatin is well tolerated, side effects like myotoxicity are reported. The mechanism for statin-induced myotoxicity is still poorly understood. Reports have suggested impaired mito...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Public Library of Science
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885717/ |